After Pfizer, Serum also sought trial permission, developed a vaccine called Covishield.

- Serum is an Indian vaccine company

New Delhi 7th December 2020 Monday

After the US vaccine company Pfizer, now the Indian vaccine company Serum Institute of India has also applied for an emergency trial of its anti-coronary vaccine.

On Saturday, Pfizer demanded that the Indian government conduct an emergency trial of its vaccine. The serum company demanded an emergency trial of its covishield vaccine.

Government sources said Serum had made the demand to the Drugs Controller General of India (DCGI). Earlier on Saturday, Pfizer sent out its application and sought formal approval to allow its vaccine to be tried.

Pfizer had previously been allowed to conduct trials in Britain and Bahrain. Serum sought permission to try his vaccine in the wider public interest. It may be recalled that Serum is the world's largest vaccine company which was mass-producing the Covishield vaccine manufactured by Oxford-AstraZeneca in India.

Serum, in collaboration with the Indian Council of Medical Research, conducted the third phase of the Covishield clinical trial across the country. The vaccine had a good effect on senior citizens and especially on patients with Covid 19. Of the four trials Serum has conducted so far, two have been in Britain and one each in India and Brazil.